Advertisement

Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer’s disease and Down Syndrome

  • M. Fountoulakis
  • N. Cairns
  • G. Lubec
Conference paper

Summary

The 14-3-3 family consists of homo- and heterodimeric proteins representing a novel type of “adaptor proteins” modulating the interaction between components of signal transduction pathways. 14-3-3 isoforms interact with phosphoserine motifs on many proteins as kinases, phosphatases, apoptosis related proteins etc. Performing protein mapping by 2D electrophoresis in human brain we identified two isoforms, 14-3-3 gamma and epsilon and decided to determine these two multifunctional proteins in several brain regions of aged patients with Alzheimer’s disease (AD) and Down Syndrome (DS) with AD neuropathology in comparison with control brains.

14-3-3 gamma and 14-3-3 epsilon proteins were increased in several brain regions of AD and DS patients.

These changes may contribute to the complex pathomechanisms of AD and AD in DS, evolving inevitably from the fourth decade of life. Deranged 14-3-3 isoforms gamma and epsilon may reflect impaired signaling and / or apoptosis in the brain as several kinases (protein kinase C, Ras, mitogen activated kinase MEK) involved in signaling and apoptotic factors as bcl-2 related proteins BAD and BAG-1 are binding to 14-3-3 motifs.

Keywords

Glial Fibrillary Acidic Protein Down Syndrome Protein Spot Down Syndrome Patient Colloidal Coomassie Blue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aitken A, Howell S, Jones D, Madrazo J, Martin H, Patel Y, Robinson K (1995) Posttranslationally modified 14-3-3 isoforms and inhibition of protein kinase C. Mol Cell Biochem 149: 41–49PubMedCrossRefGoogle Scholar
  2. Becker L, Mito T, Takashima S, Onodera K (1991) Growth and development of the brain in Down Syndrome. Progr Clin Biol Res 373: 133–152Google Scholar
  3. Bernert G, Nemethova M, Cairns N, Lubec G (1996) Decreased cyclin dependent kinase in brain of patients with Down Syndrome. Neurosci Lett 216: 68–70PubMedCrossRefGoogle Scholar
  4. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters DL (1993) Regulation and expression of the Alzheimer’s beta/A4 amyloid protein precursor in health, disease, and Down’s Syndrome. Ann NY Acad Sci 695: 91–102PubMedCrossRefGoogle Scholar
  5. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254PubMedCrossRefGoogle Scholar
  6. Braselmann S, McCormick F (1995) Bcr and Raf form a complex in vivo via 14-3-3 proteins. EMBO J 14: 4839–4848PubMedGoogle Scholar
  7. Broadie K, Rushton E, Skoulakis EM, Davis RL (1997) Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function. Neuron 19: 391–402PubMedCrossRefGoogle Scholar
  8. Chamberlain LH, Roth D, Morgan A, Burgoyne RD (1995) Distinct effects of alpha-SNAP, 14-3-3 proteins, and calmodulin on priming and triggering of regulated exocy-tosis. J Cell Biol 130: 1063–1070PubMedCrossRefGoogle Scholar
  9. Chang HC, Rubin GM (1997) 14-3-3 epsilon positively regulates Ras — mediated signaling in Drosophila. Genes Dev 11: 1132–1139PubMedCrossRefGoogle Scholar
  10. Chen F, Wagner PD (1994) 14-3-3 proteins bind to histone and affect both histone phosphorylation and dephosphorylation. FEBS Lett 347: 128–132PubMedCrossRefGoogle Scholar
  11. Conklin DS, Galaktionov K, Beach D (1995) 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci USA 92: 7892–7896PubMedCrossRefGoogle Scholar
  12. Craparo A, Freund R, Gustafson TA (1997) 14-3-3 (epsilon) interacts with the insulinlike growth factor receptor and insulin receptor substrate-1 in a phosphoserine — dependent manner. J Biol Chem 272: 11663–11669PubMedCrossRefGoogle Scholar
  13. Dawbarn D, Allen SJ (1995) Neurobiology of Alzheimer’s disease. Bios Scientifique Publishers, OxfordGoogle Scholar
  14. Dubois T, Howell S, Amess B, Kerai P, Learmonth M, Madrazo J, Chaudhri M, Rittinger K, Scarabel M, Soneji Y, Aitken A (1997) Structure and sites of phosphorylation of 14-3-3 protein: role in coordinating signal transductiion pathways. J Protein Chem 16: 513–522PubMedCrossRefGoogle Scholar
  15. Fanger GR, Widman C, Porter AC, Sather S, Johnson GL, Vaillancourt RR (1998) 14-3-3 proteins interact with specific MEK kinases. J Biol Chem 273: 3476–3483PubMedCrossRefGoogle Scholar
  16. Fanti WJ, Muslin AJ, Kikuchi A, Martin JA, MacNicol AM, Gross RW, Williams LT (1994) Activation of Raf-1 by 14-3-3 proteins. Nature 371: 612–614CrossRefGoogle Scholar
  17. Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R (1994) Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 265: 1713–1716PubMedCrossRefGoogle Scholar
  18. Fountoulakis M, Langen H (1997) Identification of proteins by matrix-assisted laser desorption ionization-mass spectroscopy following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal Biochem 250: 153–156PubMedCrossRefGoogle Scholar
  19. Greber S, Lubec G, Cairns N, Fountoulakis M (1999) Decreased synaptosomal associated protein 25 levels in brain of patients with Down Syndrome and Alzheimer’s disease. Electrophoresis (in press)Google Scholar
  20. Hsieh G, Kenney K, Gibbs CJ, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335: 924–930CrossRefGoogle Scholar
  21. Hsu SY, Kaipia A, Zhu L, Hsueh AJ (1997) Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol Encodrinol 11: 1858–1867CrossRefGoogle Scholar
  22. Ichimura T, Ito M, Itagaki C, Takahashi M, Horigome T, Ornata S, Ohno S, Isobe T (1997) The 14-3-3 proteins bind its target protein with a common site located towards the C-terminus. FEBS Lett 413: 273–276PubMedCrossRefGoogle Scholar
  23. Isobe T, Hiyane Y, Ichimura T, Okuyama T, Takahashi N, Nakajo S, Nakaya K (1992) Activation of protein kinase C by the 14-3-3 proteins homologous with Exol protein that stimulates calcium dependent exocytosis. FEBS Lett 308: 121–124PubMedCrossRefGoogle Scholar
  24. Jones DH, Martin H, Madrazo J, Robinson KA, Nielsen P, Roseboom PH, Patel Y, Howell SA, Aitken A (1995) Expression and structural analysis of 14-3-3 proteins. J Mol Biol 245: 375–384PubMedCrossRefGoogle Scholar
  25. Kumagai A, Yakowec PS, Dunphy WG (1998) 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell 9: 345–354PubMedGoogle Scholar
  26. Langen H, Roeder D, Juranville J-F, Fountoulakis M (1997) Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 18: 2085–2090PubMedCrossRefGoogle Scholar
  27. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer RJ (1996) Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins. Neurosci Lett 209: 57–60PubMedCrossRefGoogle Scholar
  28. Lee KH, Harrington MG (1997) The assay development of a molecular marker for transmissible sponsiform encephalopathies. Electrophoresis 18: 502–506PubMedCrossRefGoogle Scholar
  29. Liao J, Omary MB (1996) 14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor. J Cell Biol 133: 345–357PubMedCrossRefGoogle Scholar
  30. Martin H, Rostas J, Patel Y, Aitken A (1994) Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J Neurochem 63: 2259–2265PubMedCrossRefGoogle Scholar
  31. Mirra SS, Heyman A, McKeel D, Sumi S, Crain BJ (1991) The consortium to establish a registry for Alzheimer disease (CERAD). II. Standardisation of the neuropathologi-cal assessment of Alzheimer’s disease. Neurology 41: 479–486PubMedCrossRefGoogle Scholar
  32. Muslin AJ, Tanner JW, Allen PM, Shaw AS (1996) Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84: 889–897PubMedCrossRefGoogle Scholar
  33. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H, Onishi Y, Inukai K, Anai M, Fukushima Y, Kikuchi M, Yazaki Y, Oka Y, Asano T (1997) 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 272: 25267–25274PubMedCrossRefGoogle Scholar
  34. Peng CY, Graves RR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine 216. Science 277: 1501–1505PubMedCrossRefGoogle Scholar
  35. Petit TL, LeBoutillier JC, Alfano DP, Becker LE (1984) Synaptic development in the human fetus: a morphometric analysis of normal and Down’s syndrome neocortex. Exp Neurol 83: 13–23PubMedCrossRefGoogle Scholar
  36. Pietromonaco SF, Seluja GA, Aitken A, Elias L (1996) Association of 14-3-3 proteins with centrosomes. Blood Cells Mol Dis 22: 225–237PubMedCrossRefGoogle Scholar
  37. Robinson K, Jones D, Patel Y, Martin H, Madrazo J, Martin S, Howell S, Elmore M, Finnen MJ, Aitken A (1994) Mechanisms of inhibition of protein kinase C by 14-3-3 isoforms. 14-3-3 isoforms do not have phospholipase A2 activity. Biochem J 299: 853–861PubMedGoogle Scholar
  38. Rommel C, Radziwill G, Lovric J, Noeldeke J, Heinicke T, Jones D, Aitken A, Moelling K (1996) Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12: 609–619PubMedGoogle Scholar
  39. Rosenmann H, Meiner Z, Kahana E, Halimi M, Lenetsky E, Abramsky O, Gabizon R (1997) Detection of 14-3-3 protein in the CSF of genetic Creutzfeld-Jakob disease. Neurology 49: 593–595PubMedCrossRefGoogle Scholar
  40. Roth D, Morgan A, Burgoyne RD (1993) Identification of a key domain in annexin and 14-3-3 proteins that stimulate calcium dependent exocytosis in permeabilized adrenal chromaffin cells. FEBS Lett 320: 207–210PubMedCrossRefGoogle Scholar
  41. Seidl R, Greber S, Schuller E, Bernert G, Cairns N, Lubec G (1997) Evidence against increased oxidative DNA-damage in Down Syndrome. Neurosci Lett 235: 137–140PubMedCrossRefGoogle Scholar
  42. Skoulakis EM, Davis RL (1996) Olfactory learning deficits in mutants for Leonardo, a drosophila gene encoding a 14-3-3 protein. Neuron 17: 931–944PubMedCrossRefGoogle Scholar
  43. Tanji M, Horwitz R, Rosenfeld G, Waymire JC (1994) Activation of protein kinase C by purified bovine brain 14-3-3: comparison with tyrosine hydroxylase activation. J Neurochem 63: 1908–1916PubMedCrossRefGoogle Scholar
  44. Tierney MC, Fisher RH, Lewis AJ, Torzitto ML, Snow WG, Reid DW, Nieuwstraaten P, Van Rooijen LAA, Derks HJGM, Van Wijk R, Bischop A (1988) The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease. Neurology 38: 359–364PubMedCrossRefGoogle Scholar
  45. Toker A, Ellis CA, Sellers LA, Aitken A (1990) Protein kinase C inhibitor proteins. Purification from sheep brain and sequence similarity to lipocortins and 14-3-3 proteins. Eur J Biochem 191: 421–429PubMedCrossRefGoogle Scholar
  46. Toker A, Sellers LA, Amess B, Patel Y, Harris A, Aitken A (1992) Multiple isoforms of a protein kinase C inhibitor (KCIP-1/14-3-3) from sheep brain. Eur J Biochem 206: 453–461PubMedCrossRefGoogle Scholar
  47. Vincenz C, Dixit VM (1996) 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecule. J Biol Chem 271: 20029–20034PubMedCrossRefGoogle Scholar
  48. Wang HG, Takayama S, Rapp UR, Reed JC (1996) Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci 93: 7063–7068PubMedCrossRefGoogle Scholar
  49. Watanabe M, Isobe T, Ichimura T, Kuwano R, Takahashi Y, Kondo H (1993) Molecular cloning of rat cDNAs for beta and gamma subtypes of 14-3-3 proteins and developmental changes in expression of their mRNAs in the nervous system. Brain Res Mol Brain Res 17: 135–146PubMedCrossRefGoogle Scholar
  50. Weber T, Otto M, Bodemer M, Zerr I (1997) Diagnosis of Creutzfeld’ Jakob disease and related human spongiform encephalopathies. Biomed Pharmacother 51: 381–387PubMedCrossRefGoogle Scholar
  51. Xing H, Kornfeld K, Muslin AJ (1997) The protein kinase KSR interacts with 14-3-3 protein and Raf. Curr Biol 7: 294–300PubMedCrossRefGoogle Scholar
  52. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ, Cantley SC (1997) The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 91: 961–971PubMedCrossRefGoogle Scholar
  53. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeld-Jakob disease. Ann Neurol 43: 32–40PubMedCrossRefGoogle Scholar
  54. Zha J, Harada H, Yang E, Jockei J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619–628PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • M. Fountoulakis
    • 1
  • N. Cairns
    • 2
  • G. Lubec
    • 3
  1. 1.F. Hoffmann-La Roche Ltd.BaselSwitzerland
  2. 2.Brain Bank, Institute of PsychiatryUniversity of LondonUK
  3. 3.Department of PediatricsUniversity of ViennaWienAustria

Personalised recommendations